JCR Pharmaceuticals Co., Ltd. announced that its Board of Directors resolved at a meeting held on April 25, 2024 change personnel change as follows: Change of Corporate Officer (As of June 26, 2024). The new title of Anne Bechet is Senior Corporate Officer, Executive Director, Clinical Development, General Manager, JCR Europe B.V., Director, JCR Luxemburg S. A and CEO, JCR USA Inc. Current Title is Clinical Development (Acting Officer), General Manager, JCR Europe B.V. and Director, JCR Luxemburg S.A.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
574 JPY | +6.30% | -0.17% | -51.02% |
12:16pm | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
May. 27 | Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 560 Yen From 1,200 Yen, Keeps at Hold | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.02% | 430M | |
+39.67% | 734B | |
+32.83% | 591B | |
-5.96% | 350B | |
+14.83% | 315B | |
+1.81% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+5.78% | 161B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024